IMOS:NASDAQChipMOS TECHNOLOGIES INC. Analysis
Data as of 2026-07-31 - not real-time
$47.40
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
ChipMOS posted record quarterly revenue, delivering the highest monthly and quarter figures since 2014 and posting double‑digit year‑over‑year growth, which has helped lift the 20‑day SMA above both the 50‑day and 200‑day averages, suggesting a short‑term bullish bias. However, the stock trades at a trailing P/E of over 60 versus an industry average of 33, margins remain thin, free cash flow is negative, and the payout ratio hovers near 100%, raising concerns about dividend sustainability. Technicals are mixed: the RSI sits in the mid‑30s hinting at possible oversold conditions, while the MACD remains bearish with a widening negative histogram, and volume is trending down, indicating waning participation.
Given the high beta of around 2, extreme 30‑day volatility (>100%), and a recent max drawdown of roughly 40%, the equity carries significant market and liquidity risk. The combination of elevated valuation multiples, debt‑heavy balance sheet, and geopolitical exposure in Taiwan suggests a cautious stance, with upside limited to continued revenue momentum but downside potential if earnings fail to catch up.
Given the high beta of around 2, extreme 30‑day volatility (>100%), and a recent max drawdown of roughly 40%, the equity carries significant market and liquidity risk. The combination of elevated valuation multiples, debt‑heavy balance sheet, and geopolitical exposure in Taiwan suggests a cautious stance, with upside limited to continued revenue momentum but downside potential if earnings fail to catch up.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish moving‑average crossover (20‑day above 50‑day and 200‑day)
- Bearish MACD histogram and line below signal
- Decreasing volume indicating weakening buying pressure
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong revenue growth but thin margins and negative free cash flow
- High valuation multiples relative to peers
- Elevated beta and volatility amplifying market risk
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Overvaluation with P/E far above industry average
- Heavy debt load and near‑full payout ratio threatening dividend durability
- Geopolitical exposure in Taiwan and high sector cyclicality
Key Metrics & Analysis
Financial Health
Revenue Growth25.40%
Profit Margin3.25%
P/E Ratio61.6
ROE3.33%
ROA2.19%
Debt/Equity64.29
P/B Ratio2.2
Op. Cash Flow$3.3B
Free Cash Flow$-231215008
Industry P/E32.8
Technical Analysis
TrendBullish
RSI35.9
Support$43.51
Resistance$78.35
MA 20$62.53
MA 50$61.47
MA 200$41.87
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$2,210.47
GradeOvervalued
TypeGrowth
Dividend Yield1.62%
Risk Assessment
Beta2.05
Volatility107.24%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.